Varenicline Pharmaceutical Overview
Champix 0.5 mg / 1 mg Pfizer tablets are varenicline tartrate formulations developed as partial agonists of α4β2 nicotinic acetylcholine receptors. Varenicline demonstrates dual-action binding properties, providing both agonistic effects to maintain baseline dopamine levels and antagonistic blocking of nicotine binding sites in neuroreceptor studies. This mechanism makes it valuable for investigating smoking cessation pathways and nicotinic receptor modulation research. At Stroid UK Shop, these pharmaceutical-grade tablets enable comprehensive analysis of varenicline’s neurochemical interactions.
Neuroreceptor Research Applications
Research laboratories study Champix formulations to examine varenicline’s effects on mesolimbic dopamine pathways and reward system modulation. Studies evaluate how partial α4β2 receptor agonism influences neurotransmitter release patterns compared to full nicotine binding. The graduated dosing approach (0.5 mg and 1 mg strengths) allows researchers to investigate dose-dependent responses in nicotinic receptor binding assays. Laboratories examining addiction neurobiology utilise these tablets to study withdrawal symptom mechanisms and craving reduction pathways. Researchers exploring our varenicline research collection can access multiple dosage formulations. Comparative studies often examine varenicline alongside traditional nicotine replacement methodologies to evaluate efficacy differences in preclinical models. Additionally, researchers investigating receptor selectivity compare varenicline’s α4β2 specificity against other nicotinic receptor subtypes including α3β4 and α7 variants. These pharmaceutical tablets also serve in pharmacokinetic studies examining varenicline metabolism and bioavailability parameters.
Compound Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Varenicline Tartrate |
| Dosage Forms | 0.5 mg / 1 mg tablets |
| Manufacturer | Pfizer Pharmaceuticals |
| CAS Number | 249296-44-4 (tartrate) |
| Storage Requirements | Room temperature, dry conditions |
| Research Grade | Pharmaceutical standard |
Researchers studying neuroplasticity mechanisms often combine varenicline investigations with other neuropharmacological compounds available in our selective androgen receptor modulators and peptide research collections.
Laboratory Compliance
Champix 0.5 mg / 1 mg Pfizer tablets are supplied exclusively for in-vitro research applications and laboratory analysis. These pharmaceutical formulations are not intended for human consumption, therapeutic use, or clinical administration. Research institutions must maintain appropriate licensing for pharmaceutical compound studies and ensure proper storage conditions. All varenicline research must comply with institutional guidelines and local regulations governing controlled pharmaceutical investigations.
